advertisement
Posted inOp-Eds, Opinion

Lisa Jarvis: Five key questions about Medicare’s new drug pricing

After months of speculation, the Centers for Medicare and Medicaid Services (known as CMS) has finally released the list of medicines that will be subject to the agency’s new price-negotiating powers. The list should give the public hope that — assuming legal challenges from drugmakers are defeated — the program could yield significant savings and […]